NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

The Nordic biotech and healthcare stocks continue to create opportunities for investors with a risk appetite. In the past week, Saniona and Evaxion Biotech raised capital, while Ascendis Pharma and Expres2ion Biotech announced their 2023 results. No companies reported any pipeline development.

7 of the 20 companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Y-mAbs Therapeutics is the best-performing Danish stock year-to-date with a 92% return and Odinwell AB was the best investment last week.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you to invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Ascendis Pharma

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results (Link)

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Link)

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

No news the past week

Curasight

No news the past week

Evaxion Biotech

Evaxion Announces Closing of $15 Million Public Offering (Link)

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement (Link)

ExpreS2ion

ExpreS2ion announces financial results for the fourth quarter and full-year 2023 (Link)

Fluoguide

No news the past week

Genmab

No news the past week

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

Saniona publishes outcome in rights issue (Link)

Scandion Oncology

No news the past week

SynAct Pharma

SynAct Pharma AB will publish its Q4 report for 2023 on February 23 at 07.30 CET. (Link)

Notice of extraordinary general meeting in SynAct Pharma AB (Link)

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of -3.5%. The most notable news were capital raises by Saniona and Evaxion Biotech rasing 88.9 MSEK 15 MUSD respectively. Ascendis Pharma and Expres2ion Biotech also announced their 2023 results. There were no major pipeline development in any of the companies. The best stocks year-to-date are Y-mAbs Therapeutics, CS Medica, and Expres2ion Biotech Holding with 58-92% increases already after six weeks of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 5.6%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 1.7% to 63.10. The index was previously recovering from the all-time low in October of 57.12 but is now on a downward trajectory again. In the past 12 months, it has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

31-46% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Odinwell AB (46%) (Nordnet) specializes in the development of medical devices addressed to wound care management. The company is developing a platform for wound care with associated technological aids to analyze and facilitate the process around wound care management. In addition to the main business, associated services are also offered.

Acarix AB (37%) (Nordnet) has developed a technology that enables the identification of coronary heart disease. The company’s product is a non-invasive test that is put with a note on the patient to analyze sound from the heart. Operations are mainly conducted in the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. 

Qlife Holding AB (31%) (Nordnet) is a medical technology company. The company specializes in the research and development of IVD units. The units are used as biomarker tests in blood and are used as a complement to other tests in healthcare. Cooperation is also carried out with other actors on the market. 

Sources: Refinitiv & Nordnet